Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: Results from Val-HeFT

European Journal of Heart Failure

Volumn 6, Issue 7, 2004, Pages 937-945

  Krum, Henry ^a,g   Carson, Peter ^b   Farsang, Csaba ^c   Maggioni, Aldo P ^d   Glazer, Robert D ^e   Aknay, Nora ^e   Chiang, Yann Tong ^e   Cohn, Jay N ^f  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d ANMCO RESEARCH CENTER   (Italy)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g ALFRED HOSPITAL   (Australia)

Author keywords

ACE inhibition; Angiotensin receptor blockade; Chronic heart failure; Mortality; Valsartan

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; NORADRENALIN; PLACEBO; QUINAPRIL; RAMIPRIL; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; FAINTNESS; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; SYNCOPE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RISK FACTORS; SINGLE-BLIND METHOD; STROKE VOLUME; SURVIVAL ANALYSIS; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 8844239987     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.09.005     Document Type: Article

References (23)

1. T.B. Levine, G.S. Francis, S.R. Goldsmith, A. Simon, and J.N. Cohn Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure Am. J. Cardiol. 49 1982 1659 1666
2. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N. Engl. J. Med. 316 1987 1429 1435
3. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N. Engl. J. Med. 325 1991 293 302
4. Consensus recommendations for the management of chronic heart failure M. Packer J.N. Cohn On behalf of the Advisory Council to Improve Outcomes Nationwide in Heart Failure (ACTION HF) Am. J. Cardiol. 83, 2A 1999 1A 38A
5. W.J. Remme, K. Swedberg European Society of Cardiology Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology Eur. J. Heart Fail. 4 2002 11 22
6. S.A. Hunt, D.W. Baker, and M.H. Chin ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J. Am. Coll. Cardiol. 38 2001 2101 2113 [Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure]
7. R. Willenheimer, E. Erdmann, F. Folath on behalf of the CIBIS-III investigators Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III EJHF 6 2004 493 500
8. J.N. Cohn, G. Tognoni Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N. Engl. J. Med. 345 2001 1667 1675
9. P. Maggioni, I. Anand, and S.O. Gottlieb Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors J. Am. Coll. Cardiol. 40 2002 1414 1421
10. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
11. M.A. Pfeffer, J.J.V. Mcmurray, and E.J. Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349 2003 1893 1906
12. M. Kawamura, M. Imanashi, Y. Matsushima, K. Ito, and K. Hiramori Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects Clin. Exp. Pharmacol. Physiol. 19 1992 547 553
13. L. Juillerat, J. Nussberger, and J. Menard Determinants of angiotensin II generation during converting enzyme inhibition Hypertension 16 1990 564 572
14. D.J. Campbell, A. Aggarwal, M. Esler, and D. Kaye Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure Lancet 358 2001 1609 1610
15. J.N. Cohn, G. Tognoni, R.D. Glazer, D. Spormann, and A. Hester Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure J. Card. Fail. 5 1999 155 160
16. T.S. Rector, and J.N. Cohn Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group Am. Heart J. 124 1992 1017 1025
17. F.H. Messerli, M.A. Weber, and H.R. Brunner Angiotensin II receptor inhibition, a new therapeutic principle Arch. Intern. Med. 156 1996 1957 1965
18. P. Manohar, and I.L. Pinam Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure Mayo Clin. Proc. 78 2003 334 338
19. H.D. White Candesartan and heart failure: the allure of CHARM Lancet 362 2003 754 755
20. U.P. Jorde, P.V. Ennezat, and J. Lisker Maximally recommended doses of angiotensin converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure Circulation 101 2000 844 846
21. M. Packer, P.A. Poole-Wilson, and P.W. Armstrong Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation 100 1999 2312 2318
22. M.F. Rousseau, M.A. Konstam, and C.R. Benedict Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor Am. J. Cardiol. 73 1994 488 493
23. H. Urata, A. Kinoshita, K.S. Misono, F.M. Bumpus, and A. Husain Identification of a highly specific chymase of the major angiotensin II-forming enzyme in the human heart J. Biol. Chem. 265 1990 22348 22357